痛風治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、病態別、流通チャネル別、地域別、セグメント予測、2025年～2030年

痛風治療薬市場の成長と動向：

Grand View Research社の最新レポートによると、痛風治療薬の世界市場規模は2030年までに41億3,000万米ドルに達すると予測されています。

市場は2025年から2030年にかけてCAGR 6.45％で成長すると予測されています。同市場の成長は、世界の疾病負担の増加、人々の認識を広めるための政府機関や民間団体による取り組み、同分野における最近の新規治療法の開拓に起因しています。さらに、臨床パイプライン医薬品の数が増加していることも、有利な市場成長機会をもたらしています。

世界では痛風の有病率が増加しており、これが市場成長を促進する重要な要因となっています。例えば、Elsevier社の論文によると、2021年にオーストラリアでは痛風の有病率が1.5%から2.9%と報告されています。同様に、2021年には、カナダと英国はそれぞれ約4％と2.33％の疾患症例の増加を報告しています。高い有病率は、高齢者人口の増加、アルコールや果糖の摂取などの不適切な食生活、座りがちなライフスタイルの増加、腎障害、心血管疾患、糖尿病などの併存疾患によってさらに裏付けられています。

強固な臨床試験パイプラインと期待される新治療薬の上市が、予測期間中の市場成長を押し上げると予想されます。現在、Jiangsu HengRui Medicine Co, Ltd.のSHR4640のような新薬候補が痛風の治療薬として第3相臨床試験段階にあります。同様に、2023年3月、Selecta Biosciences, Inc.は、SEL-212の第3相DISSOLVE I &IIプラセボ対照無作為化臨床試験の良好な結果を発表しました。SEL-212 は慢性難治性痛風に適応されます。

主要企業は、共同研究、M&A、契約、金融投資などの戦略的イニシアチブをとっており、市場成長を促進しています。例えば、2021年6月、Horizon Therapeutics plcはArrowhead Pharmaceuticalsと共同開発し、制御不能な痛風の治療薬となりうるRNAi治療薬を開発しました。2022年7月、同社は制御不能な痛風患者に対するKrystexxaの拡大承認をFDAから取得しました。この薬は免疫療法や化学療法薬のメトトレキサートと併用されます。

さらに、2023年3月、Horizon社は、全国腎臓月間キャンペーン"Weed it G'out "を実施しました。このキャンペーンでは、花と雑草を使って、尿酸が腎臓に及ぼす影響との相関関係を表現しています。このキャンペーンは、痛風に対する認識を高め、痛風を深刻に受け止め、専門医に相談するよう促すことを目的としています。

痛風治療薬市場レポートハイライト

• NSAIDsセグメントは、処方率の高さ、コストの低さ、市場での存在感の強さにより、2024年に市場で最大のシェアを占めました。
• 疾患別では、慢性疾患と比較して患者数が多いことから、急性疾患セグメントが2024年の市場シェア全体の65.77%を占めました。
• 2024年には、小売薬局がこの分野で最も高いセグメントシェアを占めています。しかし、予測期間中はオンライン薬局が最も急成長するセグメントとなる見込みです。
• 痛風患者の増加、病気治療に対する個人の意識の高さ、ヘルスケアへのアクセスの良さなどの要因により、2024年の世界市場は北米が支配的でした。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 痛風治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 痛風治療薬市場分析ツール
  • 業界分析 - ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析

第4章 痛風治療薬市場：薬剤クラスの推定・動向分析

• 世界の痛風治療薬市場：薬剤クラスダッシュボード
• 世界の痛風治療薬市場：薬剤クラスの変動分析
• 世界の痛風治療薬市場（薬剤クラス別、収益別）
• NSAIDs
• コルチコステロイド
• コルヒチン
• 尿酸値低下剤
• その他

第5章 痛風治療薬市場：病態の推定・動向分析

• 世界の痛風治療薬市場：病態ダッシュボード
• 世界の痛風治療薬市場：病態変動分析
• 世界の痛風治療薬市場（病態別、収益別）
• 急性痛風
• 慢性痛風
• 慢性痛風市場推計・予測（2018～2030年）

第6章 痛風治療薬市場：流通チャネルの推定・動向分析

• 世界の痛風治療薬市場：流通チャネルダッシュボード
• 世界の痛風治療薬市場：流通チャネル変動分析
• 世界の痛風治療薬市場（流通チャネル別、収益別）
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 痛風治療薬市場：薬物クラス、病状、流通チャネル別の地域推定・動向分析。

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年まで：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2024
  • Takeda Pharmaceutical Company Limited
  • Novartis Pharmaceuticals Corporation
  • Regeneron Pharmaceuticals Inc.
  • Merck &Co., Inc.
  • AstraZeneca
  • Arrowhead Pharmaceuticals Inc.
  • AstraZeneca
  • Teijin Pharma Ltd.
  • GSK plc.
  • Zydus Group

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 3 North America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 4 North America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 5 U.S. Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 6 U.S. Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 7 U.S. Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 Canada Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 9 Canada Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 10 Canada Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 11 Mexico Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 12 Mexico Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 13 Mexico Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 14 Europe Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 15 Europe Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 16 Europe Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Germany Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 18 Germany Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 19 Germany Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 UK Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 21 UK Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 22 UK Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 France Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 24 France Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 25 France Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 Italy Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 27 Italy Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 28 Italy Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 Spain Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 30 Spain Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 31 Spain Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Denmark Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 33 Denmark Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 34 Denmark Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Sweden Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 36 Sweden Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 37 Sweden Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Norway Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 39 Norway Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 40 Norway Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 China Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 45 China Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 46 China Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 Japan Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 48 Japan Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 49 Japan Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 India Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 51 India Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 52 India Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 South Korea Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 54 South Korea Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 55 South Korea Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Australia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 57 Australia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 58 Australia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 Thailand Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 60 Thailand Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 61 Thailand Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Latin America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 63 Latin America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 64 Latin America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Brazil Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 66 Brazil Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 67 Brazil Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Argentina Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 69 Argentina Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 70 Argentina Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 71 MEA Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 72 MEA Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 73 MEA Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 74 South Africa Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 75 South Africa Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 76 South Africa Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 77 Saudi Arabia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 80 UAE Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 81 UAE Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 82 UAE Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 Kuwait Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 84 Kuwait Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
• Table 85 Kuwait Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Gout Therapeutics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Product and Distribution Channel segment snapshot
• Fig. 10 Application segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Pharmaceutical market (USD Billion)
• Fig. 13 Market dynamics
• Fig. 14 Porter's five forces analysis
• Fig. 15 PESTLE analysis
• Fig. 16 Gout Therapeutics market: Drug Class outlook and key takeaways
• Fig. 17 Gout Therapeutics market: Drug Class movement analysis
• Fig. 18 Gout Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 NSAIDs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Colchicine market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Urate-Lowering Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Gout Therapeutics market: Disease Condition outlook and key takeaways
• Fig. 25 Gout Therapeutics market: Disease Condition movement analysis
• Fig. 26 Acute Gout market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Chronic Gout market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Gout Therapeutics market: Distribution Channel and key takeaways
• Fig. 29 Gout Therapeutics market: Distribution Channel movement analysis
• Fig. 30 Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Gout Therapeutics market revenue, by region, 2024 & 2030, (USD million)
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 North America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Key country dynamics
• Fig. 37 Target disease prevalence
• Fig. 38 U.S. gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Key country dynamics
• Fig. 40 Target disease prevalence
• Fig. 41 Canada gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 Target disease prevalence
• Fig. 44 Mexico gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Target disease prevalence
• Fig. 47 Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 Target disease prevalence
• Fig. 50 UK gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Key country dynamics
• Fig. 52 Target disease prevalence
• Fig. 53 Germany gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Target disease prevalence
• Fig. 56 France gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Target disease prevalence
• Fig. 59 Spain gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Target disease prevalence
• Fig. 62 Italy gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 Target disease prevalence
• Fig. 65 Denmark gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 Target disease prevalence
• Fig. 68 Sweden gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 Target disease prevalence
• Fig. 71 Norway gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Rest of Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Key country dynamics
• Fig. 75 Target disease prevalence
• Fig. 76 Japan gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Target disease prevalence
• Fig. 79 China gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 Target disease prevalence
• Fig. 82 India gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Key country dynamics
• Fig. 84 Target disease prevalence
• Fig. 85 Australia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Key country dynamics
• Fig. 87 Thailand gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 South Korea gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Rest of Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Key country dynamics
• Fig. 93 Target disease prevalence
• Fig. 94 Brazil gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Target disease prevalence
• Fig. 97 Argentina gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Rest of Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Key country dynamics
• Fig. 101 Target disease prevalence
• Fig. 102 South Africa gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Key country dynamics
• Fig. 104 Target disease prevalence
• Fig. 105 Saudi Arabia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Key country dynamics
• Fig. 107 Target disease prevalence
• Fig. 108 UAE gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Key country dynamics
• Fig. 110 Target disease prevalence
• Fig. 111 Kuwait gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 112 Rest of MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Gout Therapeutics Market Growth & Trends:

The global gout therapeutics market size is anticipated to reach USD 4.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.45% from 2025 to 2030. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights:

• NSAIDs segment accounted for the largest share of the market in 2024 due to the high prescription rate, low cost, and strong presence in the market.
• Based on disease condition, the acute condition segment held 65.77% of the total market share in 2024, owing to a high patient pool compared to the chronic condition
• In 2024, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
• North America dominated the global market in 2024 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Disease Condition
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class outlook
  • 2.2.2. Disease Condition outlook
  • 2.2.3. Distribution Channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Gout Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Gout Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
    • 3.3.4.1. Phase 1
    • 3.3.4.2. Phase 2
    • 3.3.4.3. Phase 2

Chapter 4. Gout Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Global Gout Therapeutics Market: Drug Class Dashboard
• 4.2. Global Gout Therapeutics Market: Drug Class Movement Analysis
• 4.3. Global Gout Therapeutics Market by Drug Class, Revenue
• 4.4. NSAIDs
  • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Corticosteroids
  • 4.5.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Colchicine
  • 4.6.1. Colchicine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Urate-Lowering Agents
  • 4.7.1. Urate-Lowering Agents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Gout Therapeutics Market: Disease Condition Estimates & Trend Analysis

• 5.1. Global Gout Therapeutics Market: Disease Condition Dashboard
• 5.2. Global Gout Therapeutics Market: Disease Condition Movement Analysis
• 5.3. Global Gout Therapeutics Market by Disease Condition, Revenue
• 5.4. Acute Gout
  • 5.4.1. Acute Gout market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Chronic Gout
• 5.6. Chronic Gout market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Gout Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Gout Therapeutics Market: Distribution Channel Dashboard
• 6.2. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
• 6.3. Global Gout Therapeutics Market by Distribution Channel, Revenue
• 6.4. Hospital Pharmacy
  • 6.4.1. Hospital Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacy
  • 6.5.1. Retail Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Online Pharmacy
  • 6.6.1. Online Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Gout Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class, Disease Condition, and Distribution Channel.

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Takeda Pharmaceutical Company Limited
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Novartis Pharmaceuticals Corporation
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Regeneron Pharmaceuticals Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Merck & Co., Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. AstraZeneca
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Arrowhead Pharmaceuticals Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. AstraZeneca
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Teijin Pharma Ltd.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. GSK plc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Zydus Group
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives